| Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin. | |
| | |
MedLine Citation:
|
PMID: 15155712 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Vasoactive intestinal peptide (VIP) is known to induce histamine release in human skin and to include a nitric oxide (NO)-dependent dilation in several other vascular beds. However, the relative contribution of histamine and NO to VIP-mediated vasodilation in human skin is unknown. Forty-three subjects volunteered to participate in two studies designed to examine the mechanism of VIP-mediated vasodilation in human skin. Study 1 examined the contribution of NO in the skin blood flow response to eight doses of VIP ranging from 25 to 800 pmol. In addition, study 1 examined a specific role for NO in VIP-mediated dilation. Study 2 examined the relative contribution of NO and histamine to VIP-mediated dilation via H1 and H2 histamine receptors. Infusions were administered to skin sites via intradermal microdialysis. Red blood cell flux was measured by using laser-Doppler flowmetry (LDF), and cutaneous vascular conductance (CVC; LDF/mean arterial pressure) was calculated and normalized to maximal vasodilation. VIP-mediated vasodilation includes a NO-dependent component at doses above 100 pmol, where NO synthase inhibition significantly attenuates CVC (P < 0.05). Inhibition of H1 receptors attenuates the rise in CVC to exogenous VIP (P < 0.05); however, combined H1-receptor inhibition and NO synthase inhibition further reduced VIP-mediated vasodilation compared with either H1 inhibition or NO synthase inhibition alone (P < 0.05). In contrast to H1-receptor inhibition, H2-receptor inhibition did not affect vasodilation to exogenous VIP. Thus, in human skin, VIP-mediated vasodilation includes a NO-dependent component that could not be explained by H1- and H2-receptor activation. |
| | |
Authors:
|
Brad W Wilkins; Linda H Chung; Nathan J Tublitz; Brett J Wong; Christopher T Minson |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. Date: 2004-05-21 |
Journal Detail:
|
Title: Journal of applied physiology (Bethesda, Md. : 1985) Volume: 97 ISSN: 8750-7587 ISO Abbreviation: J. Appl. Physiol. Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-09-10 Completed Date: 2005-04-18 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 8502536 Medline TA: J Appl Physiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1291-8 Citation Subset: IM |
Affiliation:
|
Department of Human Physiology , University of Oregon, Eugene, Oregon 97403, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Topical Adult Blood Flow Velocity / drug effects Dose-Response Relationship, Drug Female Humans Male Microdialysis / methods Nitric Oxide / metabolism* Receptors, Histamine / metabolism* Skin / blood supply*, drug effects* Skin Physiological Phenomena / drug effects* Vasoactive Intestinal Peptide / administration & dosage* Vasodilation / drug effects*, physiology* Vasodilator Agents / administration & dosage |
| Grant Support | |
ID/Acronym/Agency:
|
R01 HL-70928/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Histamine; 0/Vasodilator Agents; 10102-43-9/Nitric Oxide; 37221-79-7/Vasoactive Intestinal Peptide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Stress-related genomic responses during the course of heat acclimation and its association with isch...
Next Document: Effect of changing the gravity vector on respiratory output and control.